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Abstract   
Over the past decade, the importance of the propagation of amyloidogenic proteins 
such as α-synuclein and tau in the pathogenesis of neurodegenerative diseases has 
been supported by numerous neuropathological and experimental studies. While 
these proteins behave similarly to prions, recent evidence suggests the existence of 
fundamental differences as they can propagate in the absence of endogenous 
template, they do not exhibit a strict “strain” behavior, and they may not be 
transmissible between individuals. We therefore propose to name these proteins 
“prionoids”. In this review we critically assess the extent of the overlap between these 
two entities and evaluate how the propagation of prionoids can fit into the wider 
system dysfunction seen in the brains of patients with Alzheimer’s and Parkinson’s 
disease. 
Keywords: prionoids, neurodegeneration, prions, propagation, Alzheimer’s, 
Parkinson’s  
Prions and prionoids  
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Braak and colleagues observed that in several neurodegenerative diseases, 
pathological aggregates of proteins such as α-synuclein and tau colonize the brain 
following stereotypical patterns and suggested that this phenomenon is a result of a 
causative “agent” spreading from a starting point throughout the brain [1-3]. It is 
thought that this agent is misfolded tau and α-synuclein and that the spread of 
pathology underlies disease progression and concomitant aggravation of the clinical 
features, a notion that has been termed “Braak hypothesis” (see Glossary). This 
suggested that those proteins have the ability to transfer from cell to cell [4] , possibly 
through templated nucleation as previously described for prions [5]. We have 
therefore designated α-synuclein and tau as “prionoids” [6, 7], since they share 
propagative mechanisms with prions although they may not be transmissible 
between hosts.  
Recent observations have also challenged the Braak hypothesis, and have pointed to 
radical differences between prions and prionoids [8]. The extent of the functional and 
biological overlap between the two entities is currently a matter of intensive research 
and it is anticipated that the conclusions will shed light on the fundamental 
pathogenetic mechanisms of neurodegenerative diseases. In this article, we discuss 
whether α-synuclein and tau fulfill the criteria to be designated as bona fide prions, 
and review recently identified mechanisms that are involved in the initiation and 
development of tau and α-synuclein pathologies. 
 
Do prionoids possess critical features of bona fide prions?    
By definition, a prion is a “proteinaceous infectious particle” [9]. This is much more 
than an academic game of words: prions have been responsible for large, tragic 
epidemics, such as Kuru and iatrogenic Creutzfeldt-Jakob disease, and for enormous 
epizootics such as scrapie and bovine spongiform encephalopathy. As long as α-
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synuclein, Aβ, tau, and any other aggregating proteins are not shown to be 
“infectious” in the microbiological sense of the word, it is semantically inappropriate to 
label them as prions – hence we coined the term “prionoid”.  
But even if one abstracts from the issue of microbiological infectiousness, there are 
several additional critical differences which raise questions on the similarity between 
prions and all other prionoids. We first review which of those critical features of prions 
are shared by prionoids, in other words whether they can transfer as distinct strains, 
require endogenous template for transfer, spread from a starting point within the 
brain or the periphery, or can be transmitted iatrogenically. We then review 
mechanistic aspects underlying the transfer of prionoids between cells such as the 
mechanisms of release and uptake and the nature of the transferred species. Finally, 
we analyze the insight on the biology of propagation gained from genetics and 
neuropathology studies.  
In an attempt to clarify the nomenclature used to describe the various types of 
movement of prions and prionoids between cells, we have adopted the following 
terms in this manuscript: We use the term “propagation” only when there is cell-to-cell 
transfer of a misfolded protein with associated conformational changes of the 
endogenously expressed template. However, when the protein (misfolded or not) 
simply moves between cells without permissive templating, or when it is unknown 
whether permissive templating occurs, we refer to this procedure as “cell-to-cell 
transfer” or simply “transfer”. Finally, we use the term “spread” to refer to the 
development of misfolded protein pathology sequentially between neighboring brain 
regions. As “prionoid” we define the ordered protein aggregates that replicate 
through templated nucleation but are not (or at least not yet shown to be) infectious.         
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Evidence that prionoids propagate as distinct strains is not conclusive   
A defining feature of prions is their ability to propagate as distinct strains [10]. The 
meaning of the term strain, however, has been relaxed over time and no longer 
reflects what the original concept was meant to convey. A strain is a prion isolate that 
has specific phenotypic characteristics which, crucially, are maintained upon 
repeated passages through isogenic hosts (Figure 1) (for a detailed discussion on 
prion strains we refer the reader to previously published reviews on the topic [11, 
12]).   
There has been sporadic evidence suggesting that α-synuclein and tau might have 
strain-like properties. Specifically, it has been shown that intracerebral injection of 
brain homogenates from human brains with a variety of tauopathies has the ability to 
induce distinct tauopathies in mouse models [13]. Similar findings have been 
reported for α-synuclein [14-16]. Specifically, it has been shown that synthetic α-
synuclein can form a variety of strains that differ in their ability to cross-seed tau in 
vivo and in vitro and exhibit different profiles following proteinase K digestion [16]. 
There is limited evidence suggesting that Aβ also forms strains [17, 18], but a 
thorough characterization of the identified strains is lacking.     
A limitation of the aforementioned studies was that they did not show whether the 
identified “strains” have the ability to sustain their unique properties during several 
passages over long periods of time in vivo [19], which is a critical property of prion 
strains. This issue was partially addressed by Sanders et al [20]. The researchers 
generated cell lines stably overexpressing the aggregation-competent section of tau 
tagged with YFP and exposed them to tau fibrils through lipofection. This experiment 
led to the formation of intracellular aggregates that persisted over at least 50 days 
with passaging of the cells every two days. Single cell analyses showed 20 clones 
each with unique tau aggregate patterns. Cell lysates from those clones had the 
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ability to induce the same pattern of pathology upon treatment of naïve cultures and 
distinct pathologies after intracerebral injections in transgenic tau P301S mice. Those 
strains were also consistently passaged over several generations in vivo and back in 
vitro [20]. Even though the aforementioned studies are thorough and their results are 
interesting, they constitute only preliminary evidence that prionoid strains exist. A 
more thorough characterization of those strains is needed, along with independent 
replication of the results by several groups, which is a milestone that has not been 
achieved yet.  
 
Presence of endogenous template is not necessary for cell-to-cell transfer of 
prionoids   
Prions are unable to transfer from cell to cell in the absence of endogenous 
template [21, 22]. Recent evidence suggests that tau protein does not have this 
critical feature. Wegmann et al [23] crossed the previously published ECrTgTau mice 
expressing human tau exclusively in the entorhinal cortex [24] with mice with a tau-
null background. Surprisingly, tau could transfer from cell to cell in the absence of 
endogenous template as efficiently as in the presence of tau in the original ECrTgTau 
mice, and induced tau pathology that was indistinguishable between the two models 
[23]. However, in the knock out model, the transfer of tau was not associated with 
toxicity, indicating that the transmitted protein requires endogenous template to 
actually acquire pathogenic properties. These observations distinguish two possible 
states of transferring tau: one pathological, which is related to transfer with 
associated permissive templating (i.e. propagation), and one physiological that is 
related just to the transfer of the protein without prion-like properties and functional 
consequences. Interestingly, however, evidence for transfer of pathogenic tau protein 
without presence of endogenous template has been found in humans with Pick’s 
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disease whose hallmark neuropathological feature are tufted astrocytes [25]. It is 
known that astrocytes do not express endogenously tau, therefore the occurrence of 
tau pathology within those cells is most likely caused by transfer of misfolded protein 
from neurons, without associated templated nucleation. Therefore, the interpretation 
of the results reported by Wegmann et al is more complicated and additional 
experiments would be required to clarify the situation.  
To confirm those results, the researchers then designed agenetic reporter capable of 
identifying donor and recipient cells of tau during the transfer process [23, 26]. This 
reporter consisted of a GFP fluorophore fused to the tau protein, yet separated by the 
T2A self-cleaving peptide. The researchers then inserted this reporter into an adeno-
associated virus (AAV) and injected it into the entorhinal cortex of wild type (WT) 
mice expressing endogenous tau or of tau null mice. Staining with a human-specific 
anti-tau antibody allowed for differentiating cells that expressed tau through 
transfection (which were double positive for GFP and human tau) from cells that 
received tau through transfer (which contained human tau but not GFP) (Figure 2). 
This experiment yielded results similar to those seen in transgenic mice and thus 
supported the hypothesis that tau is probably distinct from true prions. 
 
Development of α-synuclein pathology in midbrain grafts transplanted in patients with 
PD: relation to α-synuclein transfer   
The original reports of the development of Lewy-body (LB) pathology in neurons 
grafted into the midbrain of patients with PD were considered by several scientists as 
the first evidence that α-synuclein aggregates could transfer between brain areas like 
prions [27, 28]. However, several observations contradict the hypothesis that α-
synuclein pathology in midbrain grafts transplanted in patients with PD originates 
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from the transfer of native, misfolded α-synuclein. First, LBs are concentrated in 
regions with significant reactive gliosis [29, 30]. In one case, LBs congregated 
within the part of the graft closer to the amygdala, which is a region known to be 
particularly susceptible to the development of neurodegenerative disease pathology 
[29]. Second, several patients who received midbrain grafts did not develop LB 
pathology at almost 20 years after the transplantation [31]. Interestingly, the grafts 
that were spared LB pathology were those that used dissociated neurons [31, 32], 
whereas the ones that eventually developed LBs had utilized cellular aggregates or 
tissue pieces [27, 28, 33, 34]. Third, even within the grafts that are positive for LBs, 
development of pathology was a rather rare occurrence and neurons generally 
remained alive, healthy and functional for decades after transplantation [27-29, 31, 
32, 34]. These observations argue that the development of LB pathology cannot be 
attributed (exclusively) to transfer of misfolded α-synuclein from the patients’ 
diseased tissue. Rather, development of LB pathology is most likely a reactive 
process caused by inflammation related to the grafting procedure or the 
neurodegenerative process ongoing in the host brain, or it could be related to local 
microenvironment conditions [29, 33].  
The conclusions drawn from the studies on grafted material in the brains of patients 
with PD can also aid in the interpretation of the results from mouse models. 
Numerous studies have shown that intracerebral injection of fibrillar α-synuclein in 
transgenic and non-transgenic mouse mice results in the development of widespread 
α-synuclein pathology in their brains within weeks to months [35-37]. However, the 
results from the aforementioned studies on human grafts indicate that this procedure 
can take decades in humans. This suggests that mouse models might not be 
physiologically relevant and provide only marginal support for α-synuclein 
propagation in humans because of the differences in timescale.  
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No strong evidence supporting iatrogenic transmission of AD and PD     
It is well established that Creutzfeld-Jakob disease (CJD) can be transmitted through 
human cadaveric pituitary growth hormone (c-hGH) administration [38, 39], 
transplantation of dura matter [40], and contaminated cortical electrodes [41]. To 
assess whether tau, α-synuclein and Aβ could also be transmitted between 
individuals, one group [42] studied a series of 6,190 patients who had received c-
hGH treatment and looked for evidence of neurodegenerative disease on their death 
certificates. In addition, they analyzed a series of hypophyseal neuropathological 
specimens to determine the frequency of neurodegenerative disease-associated 
pathology in a cohort presumably representative of the c-hGH donor population. This 
analysis showed that, while pathological species of tau, α-synuclein and Aβ are found 
within the hypophysis of individuals in the general population and could constitute a 
source of prionoid transmission during c-hGH administration, there is no evidence of 
development of neurodegenerative disease in c-hGH recipients. However, this study 
had several limitations [43]. First, given the long incubation time of 
neurodegenerative diseases, the subjects might have not been studied long enough 
after the treatment to allow the development of the disease. Second, no 
neuropathological assessment of the c-hGH recipients was undertaken, therefore it is 
not possible to know if the patients were truly free of tau, α-synuclein and Aβ 
pathology or if they were at the preclinical stage of the disease [43].  
Recently, two case series of patients with iatrogenic CJD (iCJD) plus Aβ pathology 
were reported [44, 45]. Those individuals had either undergone dural grafting [44] or 
treatment with c-hGH [45-47]. In the dural grafting iCJD group, five of seven patients 
developed Aβ pathology in the form of cerebral amyloid angiopathy (CAA) within the 
meningeal vessels and plaques within the gray matter, whereas 4 of 8 iCJD patients 
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treated with c-hGH developed Aβ pathology typical of AD and CAA [45]. The ages of 
the patients in both series were between 28 and 63 years old, which is too young for 
the development of such severe degree of Aβ pathology under conventional 
situations [45, 48]. An increased frequency of severe Aβ pathology was also seen in 
young patients who underwent neurosurgical procedures without developing iCJD 
[49]. The authors argue that these observations are consistent with iatrogenic 
transmission of Aβ pathology. However, an alternative explanation is that the Aβ 
pathology developed as a reactive process to the neurosurgical intervention or to 
intricacies associated with the spread of the misfolded protein from the periphery to 
the brain during c-hGH administration [44, 45].    
Finally, epidemiological studies have found no evidence supporting an infectious 
nature for α-synuclein, as conjugal transmission of PD has not been observed [50, 
51] and the incidence of PD remains relatively stable over time in various ethnical 
populations [52].  
In conclusion, the absence of evidence for infectivity supports the notion that there is 
a clear distinction between prions and prionoids. However, given that prionoids 
exhibit some behaviors that are similar to bona fide prions, these agents should still 
be treated with caution and their potential infectivity should continue being a subject 
of investigation.      
 
Does pathological α-synuclein spread from the periphery to the brain?   
The spread of bona fide prions from extraneural sites to the brain is amply 
documented [53] and its molecular underpinnings are well understood [54-56]. 
Therefore, it would be reasonable to hypothesize that a similar phenomenon occurs 
in PD and AD. According to the Braak hypothesis, α-synuclein pathology starts from 
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the brain stem within the glossopharyngeal and vagal nerve nuclei or in the olfactory 
bulb and eventually spreads to the neocortex through the midbrain [1]. Intriguingly, 
recent studies have identified α-synuclein pathology in the colon and the enteric 
nervous system in patients with PD [57-65], suggesting that the event triggering the 
initiation of the disease could occur in the periphery and ascend towards the 
brainstem through as yet undetermined paths. Consistent with a spread of α-
synuclein pathology from the periphery, one study showed that mice injected 
intramuscularly with α-synuclein fibrils rapidly developed brain pathology [66]. In 
accordance with this finding, intragastric infusion of rotenone in mice was able to 
induce α-synuclein pathology in the brain [67]. In addition, vagotomy may reduce the 
risk for development of PD in humans [68], arguably because it disrupts the migration 
pathway of pathological α-synuclein seeds from the periphery to the brain. However, 
those results did not hold up when following the same cohort over a longer period of 
time [69]. Hence, no clarity is yet attained on the possible pathways of centripetal α-
synuclein spread.     
 
Mechanistic aspects underlying the transfer of prionoids 
How is transferred α-synuclein released and taken up by the cell?  
Previous studies have indicated that transferred α-synuclein can be released from 
the cells through various mechanisms that could depend on the aggregation status of 
the protein [70], such as exosomes [71] and non-canonical vesicle-mediated 
exocytosis [72], or can be transported between neighboring cells through 
nanotunnels [73].   
Recently, a novel, unconventional mechanism underlying the cellular secretion of α-
synuclein mediated by the ubiquitin-specific protease 19 (USP19) was identified. 
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USP19 helps transport the targeted proteins to the ER. Following deubiquitination, 
the proteins are secreted from the cells via late endosomes. Interestingly, this 
pathway is used only for the secretion of α-synuclein and other misfolded proteins but 
not tau and has been termed misfolding-associated protein secretion (MAPS) [74].       
The mechanisms with which propagating α-synuclein is taken up by the recipient 
cells are still a subject of intensive investigations. However, there is evidence 
suggesting that those include endocytosis [75], heparan sulfate proteoglycans [76] 
and various cell surface receptors such as LAG3 [77].  
 
 
What is the transferred species of tau?  
The identification of the species of tau that is transferred between cells has been a 
matter of intense investigations. Takeda et al [78] used a microfluidics device system 
along with a HEK FRET biosensor tau seeding assay [76, 79] to study the transfer 
and seeding potential of various tau species derived from cortical extracts from AD 
and healthy human brains, but also from brain extracts and interstitial fluid from tau-
transgenic mice overexpressing P301L (Tg4510) or wild type tau (Tg21221). They 
found that the same seed- and transfer-competent tau species in all those cases was 
phosphorylated, high molecular weight (HMW) tau, even though it was present in low 
abundance. Using the same study systems, this group [80] further showed that a 
HMW tau species with seeding and transfer potential was also found within the 
cerebrospinal fluid (CSF) of patients with AD.  
These findings were partially consistent with those reported by Mirbaha et al [81] with 
recombinant tau repeat domain (RD) and tau isolated from human AD brains. 
Following characterization of its structure and assembly size with a variety of 
methods including size exclusion chromatography, western blotting and mass 
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spectrometry, they showed that the minimal unit internalized by HEK cells and 
primary neurons were tau trimers. The discrepancy between the findings reported by 
Takeda and colleagues and Mirbaha and colleagues could be attributed to the 
differences in study systems and sources of tau preparations used.       
Finally, a third group reported that monomeric but also aggregated tau can be 
internalized by iPSc-derived neurons. This group [82] used recombinant monomeric 
and aggregated tau preparations that were first labelled with a fluorescent dye and 
added them to the conditioned medium of iPSc-derived neurons. They found that 
monomeric tau entered the cells in two phases: a rapid endocytosis- and a slower 
micropinocytosis-like phase. On the other hand, aggregated tau entered the cells 
using a mechanism consistent with endocytosis. The findings reported by this group 
[82] contradict those by Takeda et al and Mirbaha et al; however, the discrepancy 
could be explained by the fact that they conducted their experiments on a different 
cell type using tau that was tagged with a synthetic fluorophore.  
In conclusion, there is still confusion regarding the transferring species of tau. 
Discrepancies between publications could be attributed to the use of different study 
systems which, in any case, are artificial systems that probably do not accurately 
represent the physiology in the human brain. Therefore, extrapolation of the results to 
humans should be done with caution. In addition, as previously argued, it is possible 
that the cell-to-cell transfer of prionoids could either be a physiological, benign 
phenomenon, or a more sinister phenomenon involving permissive templating. 
without the two situations being mutually exclusive; this could potentially be a factor 
cofounding the design of experiments and interpretation of their results.     
 
Novel mechanisms mediating the aggregation of tau  
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Recently, liquid-liquid phase separation (LLPS) was recognized as an important 
mechanism underlying the initiation of the aggregation for various amyloidogenic 
proteins within the cell such as FUS [83], hnRNPA1 and TDP43 [84]. The same 
phenomenon may also be involved in the initiation of tau aggregation, which could 
represent the first step towards tau cell-to-cell transfer. To test this hypothesis, 
Wegmann et al used r ecombinant phosphorylated or mutant tau and showed that it 
can form liquid droplets both in vitro and within cells [85]. HMW tau isolated from AD 
brains also showed similar properties in vitro. In addition, immunostaining of paraffin 
embedded brain slices from a patient with AD revealed the presence of droplet-like 
formations within neurons located in the cortex and hippocampus, consistent with the 
occurrence of LLPS in vivo. It would be interesting to assess whether disruption of 
LLPS could halt the aggregation and transfer of tau, and whether α-synuclein also 
undergoes LLPS during aggregation.    
 
Relation between amyloid aggregation and tau cell-to-cell transfer    
The amyloid cascade hypothesis posits that Aβ deposition in the form of plaques 
precedes and promotes neurofibrillary tangle (NFT) formation, therefore initiating 
the pathogenetic cascade that leads to the development of AD [86]. However, recent 
observations have brought this hypothesis into question. Here we discuss the 
evidence for and against the amyloid cascade hypothesis and mechanisms with 
which Aβ could influence tau transfer.     
Recently, two neuropathological diseases overlapping with AD were recognized as 
separate entities: Primary age-related tauopathy (PART) and pathological ageing. 
PART is characterized by tau pathology fitting the Braak staging and ranging from 
mild to severe stage IV, with no or mild Aβ pathology (Thal staging 0 to II) [87, 88]. 
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Affected individuals usually have mild dementia and the clinical features correlate 
well with the severity of the tau pathology and the degree of hippocampal atrophy 
[89]. Conversely, in pathological ageing there is significant Aβ pathology but minimal 
tau pathology in critical regions such as the cortex and limbic system. The individuals 
with this condition do not have the neuronal loss, dendritic pathology and synaptic 
abnormalities seen in AD and do not exhibit cognitive decline [90]. Finally, it has 
been observed that in AD the disease severity correlates well with the severity of tau 
pathology but not Aβ pathology [91]. These three observations suggest that Aβ 
deposition is a secondary event with minimal importance in disease pathogenesis, 
with tau deposition being the main event promoting neurodegeneration and disease 
progression.      
However, there is a plethora of evidence pointing in the opposite direction. First, 
mutations in genes involved in Aβ metabolism are fully penetrant and lead to early 
onset AD (EOAD), whereas only risk haplotypes and risk factors within MAPT can be 
found in AD [92, 93]; therefore, the genetic contribution of Aβ seems stronger than 
that of tau dyshomeostasis. Second, data that is almost 20 years old suggests that 
Aβ can enhance the formation of tau pathology [94, 95]. This observation was 
recently revisited and expanded upon by Pooler and colleagues, aiming to assess 
the effect of Aβ not just on tau pathology but also on tau transfer [96]. The 
researchers crossed rTgTauEC mice [24] with APP/PS1 mice developing Aβ 
pathology at a young age. At 16 months of age, the mice showed a significant 
increase in the number of cells within the dentate gyrus and CA1 region of the 
hippocampus that were positive for tau when compared to rTgTauEC mice, 
suggesting an increase in cell-to-cell transfer [96].      
Researchers from the same group [97] further assessed this phenomenon by using a 
previously developed tau HEK biosensor FRET system [76, 79]. Brain homogenates 
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from human brain samples with tau pathology with and without coexistence of Aβ 
pathology were subjected to the tau seeding assay which showed that tau from 
human brain samples with Aβ plaques could induce seeding more efficiently 
compared to tau from cases without Aβ plaques. The same effect was also seen 
when using brain lysates from APP/PS1xrTg4510 mice exhibiting both plaques and 
tangle pathology vs brain lysates from rTg4510 mice with only tangle pathology [97]. 
The enhanced seeding effect was in fact seen even before the mice developed 
plaques.     
More recently, researchers from a different group provided extensive in vivo evidence 
supporting the observations detailed above [98]. He et al. injected wild type mice and 
APP-KI mice (which develop Aβ plaques but do not overexpress tau) with sarkosyl-
insoluble tau extracted from human AD cases. The APP-KI mice developed tau 
pathology in the vicinity of Aβ plaques. They also found that the microenvironment 
around the Aβ plaques was exceedingly conducive for the expansion of tau seeds 
into larger aggregates.           
How can those seemingly contradictory pieces of evidence concerning the sequence 
of events on Aβ and tau dysfunction be reconciled into a single theory? It is possible 
that the disease initiates with soluble phase Aβ toxic species which trigger the 
cascade leading to tau pathology and overt neurodegeneration [99]. Sedimentation of 
soluble Aβ into plaques could just be a secondary phenomenon occurring later during 
disease progression, with no bearing of the number and location of the plaques on 
disease progression and on the severity of clinical features [87, 88, 91, 100]. 
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Insights gained from genetics and neuropathology studies  
Recent genetic findings on PD and AD and their relation with the transfer of tau and 
α-synuclein between cells   
 Several genome wide association studies (GWAS) conducted over the past five 
years [101, 102] [103, 104] have shown that a wide variety of processes contribute to 
the pathogenesis of neurodegenerative diseases such as AD and PD.  
Within the past ten years, over 40 risk loci have been discovered for PD through 
GWAS [101, 102, 105, 106]. Even though at many of the associated loci the true 
functional gene is uncertain, many of the putative causative genes have functions 
related to the mitochondria, lysosomes and endosomes [107] and it is plausible that a 
primary dysfunction of those systems could induce the transfer of α-synuclein 
between cells. The cellular overload with misfolded protein that cannot be cleared 
efficiently would have to be disposed of through alternative methods, with a side 
effect being the spread (spillover) between cells. Such a process (MAPS) has been 
recently described for α-synuclein [74].  
On the other hand, the situation appears to be less clear for AD. Genetics studies 
have pointed to a contribution of genes involved in inflammation pathways, lipid and 
cholesterol metabolism and vesicle recycling such as ApoE, TREM2, CR1, ABCA7, 
CLU, CD33, and SORL1 [103, 108-110]. It is unknown how a dysfunction of such 
pathways could be associated with the transfer of tau and Aβ. One could hypothesize 
that lipid dysfunctions, or immunological deficiencies, may damage the cell 
membrane of neurons. This, in turn, could lead to the release of misfolded tau that is 
taken up by neighboring neurons, ultimately leading to spread of the pathology 
(Figure 3). In fact, two recent publications have shown that Aβ accumulates in 
response to infections by herpes simplex virus, Candida albicans and Salmonella 
enterica in an attempt to sequester the pathogenic agent [111-113]. However, this 
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process can go awry resulting in overt Aβ pathology triggering the cascade leading to 
AD.   
In conclusion, the results from the genetic studies support that a wider system 
dysfunction causes PD and AD. It is important to determine through future studies 
how does the transfer and aggregation of misfolded protein fit into the larger picture.   
 
 
A substantial proportion of cases deviate from the Braak pattern  
There are several weaknesses regarding the Braak theories for the progression of 
neurodegenerative diseases [33, 114]. First, the sequential pattern for the 
development of LB pathology is not followed in a significant proportion of PD cases 
[115, 116] but also in dementia with Lewy bodies (DLB) [117]. Second, α-synuclein 
pathology is absent from some genetic forms of PD such as parkin and several cases 
of LRRK2 [107]. Third, LBs can be found in healthy individuals [118]. Fourth, LB 
pathology does not correlate well with clinical features [119], similarly to Aβ pathology 
[91].  
Deviations from the Braak hypothesis are also seen in the case of AD. According to 
mouse models used to study tau propagation that express human tau exclusively in 
the entorhinal cortex (EC) [24, 120, 121], the site to which tau spreads after the initial 
appearance of pathology in the EC is the dentate gyrus [122]. However, this pattern 
is not followed in humans because the dentate gyrus is affected at a later stage. 
Second, sometimes patients with AD do not fit in with the typical Braak staging as the 
hippocampus develops only mild tau pathology; alternatively, tau pathology can be 
present almost exclusively in the temporal lobe from where it eventually spreads to 
the hippocampus but nowhere else [123].  
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While neuropathology studies are directly informative only about deposition of 
misfolded proteins and not necessarily about cell-to-cell transmission, the 
aforementioned observations would support the notion that transfer of misfolded 
proteins from cell to cell are not responsible for the progression of the pathology seen 
in patients with AD and PD. However, it might just be the case that the PD and AD 
entities require reclassification to account for the different disease forms and related 
underlying pathogenetic mechanisms [107]; it is possible that α-synuclein and tau 
spreading is important in some forms of disease but has no or a minor role in others. 
       
Concluding remarks  
Since the first description of propagation phenomena in neurodegenerative diseases 
10 years ago, it has become clear that this mechanism probably is not the main 
phenomenon involved in disease progression, and that the situation is more complex 
with crucial involvement of other mechanisms such as immunological dysfunction. 
We propose that protein propagation should be investigated in the context of a 
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Figure 1: The definition of a “strain”: Prion strains are prion protein species that 
can induce a certain type of pathology in the host organism, can be recovered and 
can induce the same type of pathology when introduced de novo in the naïve host 
organism. The passaging is still effective over several generations.    
Figure 2: Assays used to study the propagation of prions and prionoids. Tau: 
A.The GFP-2a-tau genetic reporter is inserted into an AAV and can be used in vivo 
and in vitro to transfect primary neurons. B.HEK tau bionsensor FRET cells. HEK 
cells stably overexpress tau-CFP and tau-YFP. After adding tau fibrils or other tau 
preparations that can induce seeding, the cells develop inclusions that are FRET-
positive. α–synuclein: D. HEK cells stably overexpressing  α–synuclein. Addition of 
α–synuclein fibrils induces aggregation and phosphorylation of endogenous α–
synuclein that can be detected using an anti-phospho-synuclein antibody. α–
synuclein and tau: C. Injection of α–synuclein or tau fibrils in the brain of transgenic 
mice overexpressing α–synuclein or tau respectively induces widespread pathology 
that progresses through the brain. Prions: E. pK digestion assay: Brain is 
homogenized, treated with pK digestion and run on the western blot to compare the 
cleavage pattern with non-infections PrP. F. Protein misfolding cyclic amplification 
assay (PMCA): Misfolded protein is incubated with normal protein which undergoes 
conformational changes. Several treatment cycles with ultrasound break up the 
elongating misfolded structures thus leading to the production of more aggregating 
proteins. G. Scrapie cell assay: Misfolded PrP is added to N2a cell cultures that are 
passaged several times. The percentage of positive cells is determined through 
automatic cell counting. H. Mouse bioassay: Transgenic mice that overexpress PrP 
are injected with infectious PrPsc that induces widespread pathology.  
Figure 3: Proposed model for the pathogenesis of AD: In this model, the core 
event in the pathogenesis of AD is the membrane damage in the dendrites of 
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neurons located within the entorhinal cortex. The following steps lead to and follow 
this central event: 1) Various events trigger the generation of toxic species of soluble 
Aβ. Such events include mutations within APP, PS1 and PS2 or infections. The 
location where this phenomenon occurs is unknown though it is most likely within the 
cortex. 2) The toxic Aβ species travel through the CSF throughout the brain but affect 
primarily the neurons in the entorhinal cortex that are selectively vulnerable. 3) The 
toxic Aβ species induce membrane damage on the dendrites which leads to the 
release of misfolded tau into the interstitial fluid and to the activation of a localized 
immune response and repair mechanism including molecules such as ApoE, TREM2, 
ABCA1, CR1 etc. The membrane damage is aggravated through a positive feedback 
loop. 4) The misfolded tau that has been released from the damaged neurons can be 
uptaken by synaptically connected, healthy neurons, leading to the propagation of 
the NFT pathology across neuronal networks, following the Braak staging pattern. 5) 
Soluble Aβ deposits throughout the brain in the form of plaques, which have little 
importance for the pathogenesis of the disease. The cortex is the location where the 
initial event leading to the generation of toxic Aβ species occurs; therefore, their 
concentration first reaches critical levels that allows their sedimentation as plaques 
within the cortex.   
 
